Stock 4AB ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AbbVie Inc. Deutsche Boerse AG

Equities

4AB

US00287Y1091

Market Closed - Deutsche Boerse AG
Other stock markets
 13:56:04 01/07/2024 BST 		5-day change 1st Jan Change
159.5 EUR +0.34% Intraday chart for AbbVie Inc. -0.68% +14.61%
07-01 Merus Names New Chief Medical Officer MT
07-01 AbbVie: new CEO takes up post CF

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
PR
AbbVie - Introducing Alle Payment Plans, Powered by Cherry
AQ
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PR
AbbVie Acquires Celsius Therapeutics
PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma
AQ
Introducing Allē Payment Plans, Powered by Cherry
PR
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
PR
AbbVie Provides U.S. Regulatory Update on ABBV-951
AQ
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
PR
AbbVie Declares Quarterly Dividend
AQ
AbbVie Declares Quarterly Dividend
PR
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
PR
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
PR
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
PR
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
PR
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
PR
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
AQ
AbbVie - SkinMedica Celebrates 25 Years of Empowering Radiant Skin
AQ
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
PR
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. 4AB Stock
  5. News AbbVie Inc.
  6. Press Releases